2021 ASCO Virtual Meeting: Leukemia TALK

Expert perspectives on trial designs, study populations, safety/efficacy results, and practical implications from the 2021 ASCO (American Society of Clinical Oncology) and EHA (The European Hematology Association).

Funding from Amgen Oncology and Takeda Oncology/Content Developed Independently by OncLive

EP. 1: OPTIC Primary Analysis: a Dose-Optimization Study of 3 Starting Doses of Ponatinib in CML Treatment

July 8th 2021

Jorge Cortes, MD, reviews the results of the OPTIC trial: a dose-optimization study of 3 starting doses of ponatinib.

EP. 2: Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

July 8th 2021

Elias Jabbour, MD, highlights early findings from a phase 2 study of the combination of ponatinib and blinatumomab in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

EP. 3: GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

July 8th 2021

Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.

EP. 4: GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL

July 8th 2021

Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.

EP. 5: MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

July 8th 2021

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).